Ngenla
Authorised
This medicine is authorised for use in the European Union
somatrogon
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Ngenla is a medicine used to treat children and adolescents who are not growing at the normal rate as a result of growth hormone deficiency (lack of natural growth hormone). It is given to patients from 3 years of age.
Ngenla contains the active substance somatrogon.
Ngenla can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of children and adolescents with growth hormone deficiency.
Ngenla is available as an injection in pre-filled pens of different strengths, to be given under the skin once a week. The recommended dose is 0.66 mg per kilogram of body weight each week, adjusted by the doctor if necessary. For patients over 45 kg who require doses higher than 30 mg the dose is given as two injections. Patients or their caregivers can inject the dose themselves after appropriate training.
For more information about using Ngenla, see the package leaflet or contact your doctor or pharmacist.
In healthy patients, growth hormone is released by the pituitary gland (a gland at the base of the brain). It is important for growth during childhood and adolescence. Growth hormone also affects how the body handles proteins, fat and carbohydrates. The active substance in Ngenla, somatrogon, is a version of natural human growth hormone which has been modified by combining it with part of another human hormone called chorionic gonadotropin in a so-called recombinant hormone. Because only a part of this other hormone is used, it does not have an effect on the body, but the combination lets somatrogon remain active in the body for a longer period of time than natural growth hormone so injections do not need to be given every day.
Ngenla once a week has been shown to be at least as effective as daily somatropin (a medicine with the same structure as natural growth hormone) in promoting growth. In a main study in 224 pre-pubertal patients with growth hormone deficiency the average rate of growth over a year was 10.1 cm in those given Ngenla and 9.8 cm in those given somatropin. Other measures of growth, such as bone maturation, were also comparable between children from both groups.
The most common side effects with Ngenla (which may affect more than 1 in 10 people) are reactions at the site of injection, headache, and fever. For the full list of side effects of Ngenla, see the package leaflet.
Ngenla must not be used if the patient has an active tumour or an acute life-threatening illness. It must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). For the full list of restrictions, see the package leaflet.
Ngenla injected once per week was shown to be at least as effective as somatropin given by injection once per day. The safety profile of Ngenla was also comparable with somatropin, although injection site reactions were more common in patients treated with Ngenla. Longer-term effects will continue to be monitored after marketing. The majority of patients preferred once-weekly treatment compared with daily injections.
The European Medicines Agency therefore decided that the benefits of Ngenla are greater than its risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ngenla have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Ngenla are continuously monitored. Side effects reported with Ngenla are carefully evaluated and any necessary action taken to protect patients.
Ngenla received a marketing authorisation valid throughout the EU on 14 February 2022.
Product information
Latest procedure affecting product information:
VR/0000266074
23/04/2025
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Ngenla
- Active substance
- somatrogon
- International non-proprietary name (INN) or common name
- somatrogon
- Therapeutic area (MeSH)
- Growth and Development
- Anatomical therapeutic chemical (ATC) code
- H01AC08
Pharmacotherapeutic group
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUESTherapeutic indication
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
News on Ngenla
This page was last updated on